{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:28:17Z","timestamp":1761920897433,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013200","name":"Government of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.msard.2021.103003","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T12:47:28Z","timestamp":1620391648000},"page":"103003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate."],"prefix":"10.1016","volume":"52","author":[{"given":"Chieh-Hsin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-839X","authenticated-orcid":false,"given":"Bei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8381-694X","authenticated-orcid":false,"given":"Maryam","family":"Nakhaei-Nejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Barilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg","family":"Blevins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4042-8533","authenticated-orcid":false,"given":"Fabrizio","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103003_bib0001","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2021.103003_bib0002","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103003_bib0003","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1523-1747.2003.12605.x","article-title":"Dimethylfumarate is a potent inducer of apoptosis in human T cells","volume":"121","author":"Treumer","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.msard.2021.103003_bib0004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000017903","article-title":"Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis","volume":"196","author":"Hoxtermann","year":"1998","journal-title":"Dermatology"},{"key":"10.1016\/j.msard.2021.103003_bib0005","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/eji.1830260916","article-title":"Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate","volume":"26","author":"de Jong","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.msard.2021.103003_bib0006","doi-asserted-by":"crossref","first-page":"28017","DOI":"10.1074\/jbc.M112.383380","article-title":"Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor kappa B (NF-kappa B) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1\/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling","volume":"287","author":"Peng","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.msard.2021.103003_bib0007","article-title":"Disease modifying therapies for relapsing multiple sclerosis","volume":"354","author":"Wingerchuk","year":"2016","journal-title":"Bmj-Brit Med J"},{"key":"10.1016\/j.msard.2021.103003_bib0008","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14740338.2015.1093620","article-title":"Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis","volume":"14","author":"Faulkner","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.msard.2021.103003_bib0009","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1212\/NXI.0000000000000340","article-title":"Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis","volume":"4","author":"Ghadiri","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103003_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000432","article-title":"Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod","volume":"5","author":"Nakhaei-Nejad","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103003_bib0011","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1212\/NXI.0000000000000397","article-title":"Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation","volume":"4","author":"Wright","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103003_bib0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2019.01.007","article-title":"Factors associated with dimethyl fumarate-induced lymphopenia","volume":"398","author":"Sainz de la Maza","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103003_bib0013","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1212\/NXI.0000000000000076","article-title":"Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate","volume":"2","author":"Spencer","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103003_bib0014","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1038\/s41598-018-26519-w","article-title":"Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients","volume":"8","author":"Montes Diaz","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2021.103003_bib0015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1352458512451510","article-title":"Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis","volume":"19","author":"Tutuncu","year":"2013","journal-title":"Multiple Scler. J."},{"key":"10.1016\/j.msard.2021.103003_bib0016","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2021.103003_bib0017","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-020-01046-2","article-title":"Impact of age on multiple sclerosis disease activity and progression","volume":"20","author":"Zeydan","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2021.103003_bib0018","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients","author":"Jordan","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"year":"2018","series-title":"R: A language and Environment For Statistical Computing","author":"Core Team","key":"10.1016\/j.msard.2021.103003_bib0019"},{"key":"10.1016\/j.msard.2021.103003_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005752","article-title":"An R package for \u2018omics feature selection and multiple data integration","volume":"13","author":"Rohart","year":"2017","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.msard.2021.103003_bib0021","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","article-title":"A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy","volume":"127","author":"Du Pasquier","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103003_bib0022","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1177\/1352458515608961","article-title":"Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients","volume":"22","author":"Longbrake","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103003_bib0023","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14712598.2019.1568407","article-title":"B cell depletion in the treatment of multiple sclerosis","volume":"19","author":"Myhr","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.msard.2021.103003_bib0024","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1177\/1352458517707069","article-title":"Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count","volume":"24","author":"Longbrake","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103003_bib0025","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice","author":"Mehta","year":"2019","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:56:37Z","timestamp":1761900997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":25,"alternative-id":["S2211034821002704"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103003","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103003"}}